Banks' latest ARS settlement falls short

Under the deal, Merrill Lynch will buy back ARS at par from small individual and business investors (those with accounts of less than $4 million) by the end of September. Individuals, charities and businesses up to $100 million will have their ARS holdings redeemed by January 2 next year. In the interim, the bank will supply no-cost loans to bridge the gap. The bank accelerated an earlier buyback deal agreed earlier this month.

But the bank did not commit to redeeming larger investors, saying only that it "will use its best efforts to provide liquidity to its ARS institutional customers and business customers with accounts of more than $100 million by the end of 2009".

The bank will also pay a $125 million fine, and has agreed to arbitration over claims by investors who lost money as a result of the drop in ARS liquidity in February this year. The Securities and Exchange Commission warned Merrill Lynch faced a further penalty fine, depending on "the extent of Merrill Lynch's misconduct in marketing and selling ARS".

Goldman Sachs, meanwhile, agreed to buy back roughly $1 billion in ARS sold to smaller clients (accounts of under $10 million) by November 12, but made no commitment to larger clients, saying it would "endeavour to continue to work with issuers and other interested parties, including regulatory and government entities, to expeditiously provide liquidity solutions for institutional investors". Goldman Sachs will also pay a fine of $22.5 million.

Deutsche Bank will complete buybacks within 90 days for its retail customers, but also made no commitment on institutional ARS holders; its fine was set at $15 million.

See also: UBS commits to $18.6 billion ARS buyback 
Merrill and Citi to repurchase ARS after New York applies pressure 
New York sues UBS for alleged auction rate securities fraud  
Investors caught short by auction rate meltdown

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here